The renoprotective impact of adipose mesenchymal stem cell-derived exosomes coupled with Roflumilast | ||||
| Biochemistry Letters | ||||
| Volume 20, Issue 1, 2024, Page 91-105 PDF (747.99 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/blj.2024.297953.1059 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
bassant yahia  1; mohamed Hassan sherif2; Nashwa Barakat3; Mohamed Ali 4
| ||||
| 1Chemistry Department, Faculty of Science, Zagazig University | ||||
| 2Department of Chemistry, Faculty of science, Zagazig University. Egypt | ||||
| 3Urology and Nephrology Center, Mansoura University, Mansoura, 35516, Egypt | ||||
| 4Chemistry department, Faculty of science, Zagazig university, Zagazig, Egypt | ||||
| Abstract | ||||
| Background: Chronic kidney disease (CKD) is a global health concern characterized by the presence of irreversible kidney damage. The renoprotective role of adipose mesenchymal stromal cell-derived exosomes (ADMSCs-Exos) and roflumilast (ROF) in the management of acute kidney damage Objectives: The current study was conducted to investigate the potential therapeutic efficacy of Exos combined with ROF in the management of CKD. Material and methods: Isolating and characterizing exosomes involved using electron microscopy and flow cytometry . Rats were separated into seven groups, Control group: rats were injected with 0.9% saline. ROF group: The rats received an oral administration of ROF at a dosage of 1.2 mg/kg. Exos group: rats were given two injections of 100 μg Exos. DOX group: rats were subjected to two injections on day 1 and day 14, at a dosage of 4 mg/kg of DOX. DOX + ROF group: rats were administered ROF for a duration of 7 days following each injection of DOX. DOX + Exos group: rats were administered exosomes five days after receiving both doses of DOX. DOX + ROF+ Exos group: rats were administered both ROF and Exos subsequent to each DOX injection. Results: The isolated exosomes exhibited the characteristic cup-shaped morphology and expressed the surface proteins CD81, CD9, and CD63. The administration of ROF or Exos resulted in a notable enhancement in both renal functions and structural integrity when compared to the DOX group (p < 0.05 | ||||
| Keywords | ||||
| chronic kidney disease; Doxorubicin; Exosomes; Roflumilast | ||||
|
Statistics Article View: 129 PDF Download: 139 |
||||
